Publications

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Modifying injection methods when administering radioactive therapies may significantly reduce extravasation rates.

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

Cristiane Decat Bergerot, PhD

April 14th 2025

TPS 89 A Randomized Phase 3 Study of First-Line Saruparib (AZD5305) Plus Camizestrant Versus CDK4/6i Plus Physician’s Choice Endocrine Therapy or CDK4/6i Plus Camizestrant in Patients With HR+/HER2– Advanced Breast Cancer With BRCA1/BRCA2/PALB2 Mutations (EvoPAR-B)

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

BOLDSCIENCE;Pedram Razavi;Judith Balmaña;Stephen Luen;Mario Campone;Laura Cortesi;Norikazu Masuda;Kyong Hwa Park;Qingyuan Zhang;Emily Nizialek;Cathy Qi;Karen Cui;Sibylle Loibl;Mark Robson, MD;Filipa Lynce

Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC

"These findings are particularly significant for Japanese patients, as our treatment options have been more limited compared to other regions," according to Keiji Inoue, MD, PhD, a professor in the Department of Urology at Kochi Medical School.

Russ Conroy

New Legislation May Help Reduce Extravasation Rates in Cancer Radiology

Data from a Japanese trial add to the body of evidence supporting the favorable efficacy and safety of nadofaragene firadenovec for this NMIBC population.

Related Content

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Modifying injection methods when administering radioactive therapies may significantly reduce extravasation rates.

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS

April 21st 2025

FDA Grants EvoLiver Biopsy Test Breakthrough Device Designation for HCC

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Fostering the Future of Psychosocial Care With World Psycho-Oncology Day

MEV01 trial results show that the test achieved an 86% early-stage sensitivity and 88% specificity in surveillance of HCC among patients with cirrhosis.

Cristiane Decat Bergerot, PhD

April 14th 2025

Integrating psychosocial care into cancer care allows patients to receive emotional support, counseling, and coping strategies to help navigate treatment.

Nadofaragene Firadenovec Yields Responses in BCG-Unresponsive NMIBC

Russ Conroy